A research collaboration has been signed between Embark Biotech and Novo Nordisk to discover novel treatments for obesity and its associated metabolic pathologies. Embark Biotech is a recent spin-out from the Center for Basic Metabolic Research at University of Copenhagen; its technological platform focuses on receptors that stimulate energy expenditure without triggering the sympathetic nervous system (the ‘fight-or-flight’ response). The aim of the collaboration is to develop novel drug candidates that help people with obesity lose weight by burning off excess energy instead of storing it as fat.


Please enter your comment!
Please enter your name here